BridgeBio Oncology Therapeutics's quarterly market cap
increased
from Sep. 2025 ($917.10 Mil) to Dec. 2025 ($1,001.50 Mil) but then
declined
from Dec. 2025 ($1,001.50 Mil) to Mar. 2026 ($716.80 Mil).
BridgeBio Oncology Therapeutics's annual market cap
stayed the same
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then
increased
from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($1,001.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BridgeBio Oncology Therapeutics's Enterprise Value for Today is $424.07 Mil.
BridgeBio Oncology Therapeutics (NAS:BBOT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BridgeBio Oncology Therapeutics Market Cap Related Terms
BridgeBio Oncology Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's Market Cap falls into.
BridgeBio Oncology Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics (BBOT) has a Market Cap of $672.90 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #370 out of 1422 companies in the Biotechnology industry, placing it in the top 26%.
Is BridgeBio Oncology Therapeutics' Market Cap too high?
BridgeBio Oncology Therapeutics' current Market Cap is $672.90 Mil. The Biotechnology industry median Market Cap is 120.73. BridgeBio Oncology Therapeutics' value of $672.90 Mil is 457.4% above this industry median. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #370 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Market Cap compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #370 out of 1422 companies for Market Cap. This puts BridgeBio Oncology Therapeutics in the upper half of its industry. The industry median Market Cap is 120.73. BridgeBio Oncology Therapeutics' value of $672.90 Mil is 457.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.73, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Oncology Therapeutics's current Market Cap of $672.90 Mil is 457.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 120.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current Market Cap is $672.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Market Cap of $672.90 Mil. The current Market Cap is $672.90 Mil and 457.4% above the Biotechnology industry median of 120.73. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Market Cap is $672.90 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Business Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
